GlassScriptPhysician profile
Whitney Lyon
NPI 1780124065
$3,909.68
in general payments reported to CMS, 2019-2025
20 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,405 · 2022: $1,058 · 2023: $667 · 2024: $563 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,219.91 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $835.03 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $412.04 | 2021-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $370.50 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $224.78 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $205.63 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $97.14 | 2022-2024 | |
| Indivior INC. | $86.91 | 2021-2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $67.00 | 2024-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $62.41 | 2021-2024 | Abilify Asimtufii |
| Almatica Pharma LLC | $60.38 | 2024-2025 | Loreev Xr |
| Tris Pharma INC | $53.59 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $50.13 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $35.00 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $31.46 | 2023-2025 | Qelbree, Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.99 | 2021 | |
| Vanda Pharmaceuticals INC. | $29.11 | 2021 | |
| Eisai INC. | $18.24 | 2021 | |
| Amgen INC. | $12.73 | 2021 | |
| Genentech USA, INC. | $7.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.